Ceritinib has demonstrated impressive activity in the clinic in crizotinib-resistance patients...These findings are consistent with preclinical studies presented in this manuscript demonstrating the activity of ceritinib against G1269A and S1206Y crizotinib-resistance mutations, and its lack of potency against the G1202R mutation.